高级检索
    程颖, 黄玲. 广泛期小细胞肺癌中顺铂联合伊立替康与顺铂联合依托泊苷的比较[J]. 循证医学, 2012, 12(1): 23-25. DOI: 10.3969/j.issn.1671-5144.2012.01.009
    引用本文: 程颖, 黄玲. 广泛期小细胞肺癌中顺铂联合伊立替康与顺铂联合依托泊苷的比较[J]. 循证医学, 2012, 12(1): 23-25. DOI: 10.3969/j.issn.1671-5144.2012.01.009
    shu
    CHENG Ying, HUANG Ling. The Comparison of Cisplatin plus Irinotecan or Etoposide in Previously Untreated Patients with Small-Cell Lung Cancer with Extensive Disease[J]. Journal of Evidence-Based Medicine, 2012, 12(1): 23-25. DOI: 10.3969/j.issn.1671-5144.2012.01.009
    Citation: CHENG Ying, HUANG Ling. The Comparison of Cisplatin plus Irinotecan or Etoposide in Previously Untreated Patients with Small-Cell Lung Cancer with Extensive Disease[J]. Journal of Evidence-Based Medicine, 2012, 12(1): 23-25. DOI: 10.3969/j.issn.1671-5144.2012.01.009
    shu

    广泛期小细胞肺癌中顺铂联合伊立替康与顺铂联合依托泊苷的比较

    The Comparison of Cisplatin plus Irinotecan or Etoposide in Previously Untreated Patients with Small-Cell Lung Cancer with Extensive Disease

      摘要
    • 摘要: 自上世纪八十年代EP方案成为广泛期小细胞肺癌初始治疗的标准方案以来, 新药的涌现不断冲击EP方案, 但均未撼动其一线标准治疗的地位。然而自2002年日本临床肿瘤协作组（JCOG-9511）临床试验结果公布以来1, 以伊立替康为主的联合化疗方案风起云涌, 成为改写广泛期小细胞肺癌治疗历史的生力军。

       

      • HTML全文
      • 参考文献(4)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回